选择性激动剂和对抗剂在 purin 和 pyrimidine 受体上起作用的最新进展
Kenneth A Jacobson1, Fumio Suzuki2
1Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland.
Drug development research
|January 19, 2024
概括
本综述强调了最近在腺 (P1) 和ATP (P2) 受体研究方面的进展,重点关注各种受体亚型的新开发的选择性激动剂和对抗剂. 这些发现为有针对性的治疗干预铺平了道路.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 氨酸 (P1) 和ATP (P2) 受体在各种生理过程中至关重要.
- 了解它们的结构-活性关系 (SAR) 是药物开发的关键.
- 这些受体的选择性调制具有治疗潜力.
研究的目的:
- 审查最近对腺 (P1) 和ATP (P2) 受体的选择性激动剂和对抗剂的发展.
- 要突出针对特定受体亚型 (A1,A2,A3,P2X,P2Y) 的新型化合物.
- 讨论新受体调节器的发现和表征.
主要方法:
- 对P1和P2受体的结构-活性关系 (SAR) 的文献综述.
- 最近开发的选择性激动剂和对抗剂的汇编.
- 讨论新发现方法,包括对天然产品和异环衍生物的选.
- 提到用于表征的受体克隆和放射性联体结合试验.
主要成果:
- 部分和全A1激动剂,A2激动剂 (非丁和丁) 和A3激动剂的引入.
- 通过图书馆查发现了新的腺受体对抗剂.
- 识别了来自各种化学类的第一个选择性A3抗剂.
- 强大的P2受体激动剂和选择性的P2X抗剂的特征.
- [35S]ATP-γS的使用用于标记克隆的P2X受体亚型 (P2X1-P2X4).
结论:
- 在开发适用于腺和ATP受体的选择性配体方面取得了显著进展.
- 新的化学实体为针对P1和P2受体的治疗策略提供了新的途径.
- 目前正在进行的研究,包括受体克隆,对于进一步推进P2受体对手的开发至关重要.
相关概念视频
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
880
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
880
Opioid Receptors: Overview
847
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
847
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
978
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
978


